JP6949012B2 - Ｂ型肝炎表面抗原に対する抗体及びその使用 - Google Patents

Ｂ型肝炎表面抗原に対する抗体及びその使用 Download PDF

Info

Publication number
JP6949012B2
JP6949012B2 JP2018518466A JP2018518466A JP6949012B2 JP 6949012 B2 JP6949012 B2 JP 6949012B2 JP 2018518466 A JP2018518466 A JP 2018518466A JP 2018518466 A JP2018518466 A JP 2018518466A JP 6949012 B2 JP6949012 B2 JP 6949012B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018518466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533937A5 (enExample
JP2018533937A (ja
Inventor
ルオ、ウエンシン
チョウ、ビン
チャン、ジュアン
ユアン、チェン
チャン、ティアンイン
チャン、ジュン
シァ、ニンシャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Original Assignee
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd filed Critical Yang Sheng Tang Co Ltd
Publication of JP2018533937A publication Critical patent/JP2018533937A/ja
Publication of JP2018533937A5 publication Critical patent/JP2018533937A5/ja
Application granted granted Critical
Publication of JP6949012B2 publication Critical patent/JP6949012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018518466A 2015-10-09 2016-10-09 Ｂ型肝炎表面抗原に対する抗体及びその使用 Active JP6949012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510647977.7 2015-10-09
CN201510647977 2015-10-09
PCT/CN2016/101560 WO2017059813A1 (zh) 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020210762A Division JP2021063092A (ja) 2015-10-09 2020-12-18 Ｂ型肝炎表面抗原に対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2018533937A JP2018533937A (ja) 2018-11-22
JP2018533937A5 JP2018533937A5 (enExample) 2019-01-10
JP6949012B2 true JP6949012B2 (ja) 2021-10-13

Family

ID=58487306

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018518466A Active JP6949012B2 (ja) 2015-10-09 2016-10-09 Ｂ型肝炎表面抗原に対する抗体及びその使用
JP2020210762A Withdrawn JP2021063092A (ja) 2015-10-09 2020-12-18 Ｂ型肝炎表面抗原に対する抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020210762A Withdrawn JP2021063092A (ja) 2015-10-09 2020-12-18 Ｂ型肝炎表面抗原に対する抗体及びその使用

Country Status (10)

Country Link
US (1) US10689434B2 (enExample)
EP (1) EP3360896B1 (enExample)
JP (2) JP6949012B2 (enExample)
KR (1) KR102132604B1 (enExample)
CN (1) CN106565840B (enExample)
AU (1) AU2016334290B2 (enExample)
BR (1) BR112018007121A2 (enExample)
CA (1) CA3001231C (enExample)
ES (1) ES3041684T3 (enExample)
WO (1) WO2017059813A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001231C (en) * 2015-10-09 2022-07-12 Xiamen University Antibody against hepatitis b surface antigen and use thereof
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
NZ770866A (en) * 2018-05-31 2025-07-25 Daiichi Sankyo Co Ltd Anti-human tlr7 antibody
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
WO2020233695A1 (zh) * 2019-05-23 2020-11-26 厦门大学 抗乙肝病毒新型抗体及其用途
CN111242107B (zh) * 2020-04-26 2021-03-09 北京外号信息技术有限公司 用于设置空间中的虚拟对象的方法和电子设备
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1322761A4 (en) 2000-10-02 2005-03-23 Korea Res Inst Of Bioscience HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
US9567390B2 (en) * 2008-01-23 2017-02-14 Department Of Biotechnology Humanized high affinity recombinant antibody against Hepatitis B surface antigen
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
KR102106782B1 (ko) 2012-06-11 2020-05-07 시아먼 유니버시티 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체
CA2878155C (en) * 2012-07-10 2019-01-08 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis b virus infection
SG10201806025TA (en) * 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
CA3001231C (en) * 2015-10-09 2022-07-12 Xiamen University Antibody against hepatitis b surface antigen and use thereof

Also Published As

Publication number Publication date
CA3001231A1 (en) 2017-04-13
WO2017059813A1 (zh) 2017-04-13
JP2021063092A (ja) 2021-04-22
AU2016334290A1 (en) 2018-05-10
CN106565840A (zh) 2017-04-19
JP2018533937A (ja) 2018-11-22
CA3001231C (en) 2022-07-12
KR102132604B1 (ko) 2020-07-13
ES3041684T3 (en) 2025-11-13
US20190389939A1 (en) 2019-12-26
AU2016334290B2 (en) 2020-06-18
US10689434B2 (en) 2020-06-23
EP3360896A4 (en) 2019-08-28
BR112018007121A2 (pt) 2018-11-06
CN106565840B (zh) 2020-09-01
EP3360896B1 (en) 2025-07-23
EP3360896A1 (en) 2018-08-15
KR20180084045A (ko) 2018-07-24

Similar Documents

Publication Publication Date Title
JP7442581B2 (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
JP7332627B2 (ja) 最適化された抗ｔｌ１ａ抗体
JP7292526B2 (ja) 操作された抗ｉｌ－２抗体
TW201605901A (zh) Ｐｄ－１抗體、其抗原結合片段及其醫藥用途
RU2765878C2 (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
KR20220167331A (ko) 항-flt3 항체 및 조성물
JP7607289B2 (ja) 新規の抗ｂ型肝炎ウイルス抗体及びその使用
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
RU2841957C1 (ru) Сконструированные антитела против il-2
JP2025523375A (ja) クローディン１８．２抗体、その製造方法及び使用
CN119119268A (zh) Pvrig抗体及其制备方法和应用
JP2022538438A (ja) 百日咳毒素結合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201218

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210215

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210921

R150 Certificate of patent or registration of utility model

Ref document number: 6949012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250